Global Experts Meeting on Infectious Diseases
Yokohama University of Pharmacy,Japan
Title: EFｄA, An extremely excellent anti-HIV nucleosides -How it was developed and clinical results by Merck
Biography: Hiroshi Ohrui
4’-C-Ethynyl-2-fluoro-2’-deoxyadenosine (EFdA) has attracted much attention due to its extremely excellent anti-HIV activity, for example; 1. prevent the emergence of resistant HIV mutants, 2. over 400 times more active than AZT and several orders of magnitude more active than the other clinical reverse-transcriptase inhibitor y 2’, 3’-dideoxy-nucleoside drugs, 3. very low toxic, 4. very long acting, 5. possible use for prophylaxis, and so on.
EFdA is now under clinical investigation by Merck & Co. as MK-8591.
In the beginning, my general idea for the development of anti-viral modified nucleosides will be presented, and then the development of EFdA will be discussed and the clinical results by Merck
will be also presented.